Fig. 1From: Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centersStudy design. After confirming a diagnosis of migraine, consecutive eligible patients were enrolled. After the baseline period of more than 4 weeks, the enrolled patients were treated with 3 doses of one of the CGRP mAbsBack to article page